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Terms of Reference
 Review current data on efficacy, effectiveness, immunogenicity, and cost-
effectiveness of pneumococcal vaccines
 Review current recommendations considering up-to-date evidence, 
including epidemiological studies, and assess strength of the evidence
 Revise or update recommendations for pneumococcal vaccine use, as 
needed
Pneumococcal Conjugate Vaccine Recommendations
PCV13 for 
children
PCV13 for individuals with 
immunocompromising 
conditions
PCV13 in series with 
PPSV23 for adults 
≥65 years old
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Evaluation of 
PCV13 in adults 
≥65 years old
2014 ACIP Age Based Recommendation
 In 2014 when ACIP recommended PCV13 in series with PPSV23 for adults 
≥65 years old, the rationale was:
–
–
Recommendation was warranted in the short-term because there was 
still a significant burden of disease among older adults, particularly 
due to pneumococcal pneumonia
The public health benefits in the long-term, however, were expected 
to be limited since the indirect effects from pediatric PCV13 use were 
expected to increase
 Therefore, the recommendation was made with a commitment to re-
evaluate this policy 4 years later and revise as needed
Policy Question
 Should PCV13 be administered routinely to all immunocompetent* 
adults aged ≥65 years in the context of indirect effects from 
pediatric PCV use experienced to date?
–
–
–
–
Population: Immunocompetent adults 65 years and older
Intervention: PCV13 in series with PPSV23, in the context of 
indirect effects
Comparison(s): PPSV23 alone, in the context of indirect effects
Outcomes: Invasive pneumococcal disease (IPD), pneumonia, 
mortality, safety
Population Covered by the Policy Question
Immunocompetent adults 65 years and older are the focus of the current 
policy discussion
Not included in the current policy discussion:
 Adults ≥19 years old with an immunocompromising condition including:
– Recommended to receive PCV13 in series with PPSV23 (ACIP 2012)
• Chronic renal failure 
• Nephrotic syndrome 
• Immunodeficiency 
• Iatrogenic immunosuppression
• HIV
• Cochlear implants
• CSF leaks
• Generalized malignancy
• Hodgkin disease
• Leukemia or Lymphoma
• Multiple myeloma
• Solid organ transplants
• Congenital or acquired asplenia
• Sickle cell disease or other hemoglobinopathies
Proposed Policy Options for Today’s Vote
A. ACIP recommends PCV13 for all adults ≥65 years who have not 
previously received PCV13.  PCV13 should be given first, followed by a 
dose of PPSV23.
B. ACIP recommends PCV13 based on shared clinical decision making for 
adults ≥65 years who do not have an immunocompromising 
condition* and who have not previously received PCV13. All adults 
≥65 years should receive a dose of PPSV23. 
C. ACIP no longer recommends PCV13 for adults ≥65 years who do not 
have an immunocompromising condition.* All adults ≥65 years 
should receive a dose of PPSV23.
Workgroup Rationale
 Goal is to re-evaluate the 
2014 policy to 
recommend PCV13 in 
series with PPSV23 for 
adults ≥65 years
 Propose initial focus on 
whether to continue the 
current recommendation 
or not
Continue 2014 
Recommendation?
Yes No*
Workgroup Rationale
 Goal is to re-evaluate the 
2014 policy to 
recommend PCV13 in 
series with PPSV23 for 
adults ≥65 years
 Propose initial focus on 
whether to continue the 
current recommendation 
or not
Continue 2014 
Recommendation?
Yes No*
Shared Clinical
Decision-
Making
 
No longer 
recommend
Today’s Pneumococcal Vaccines Session
 Considerations for PCV13 use among adults 65 years and older and a 
summary of the Evidence to Recommendations— Dr. Almea Matanock 
(CDC/NCIRD) 
 Proposed policy options— Dr. Almea Matanock (CDC/NCIRD) 
 Feedback from liaison and ex-officio members on the policy options 
proposed
 Discussion about the considerations for PCV13 use among adults ≥65 
years old
